Sintilimab plus chemo vs chemo alone for advanced ENKTL lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lymphoma called ENKTL (extranodal natural killer/T-cell lymphoma).
- Your lymphoma must be at an advanced stage (widely spread).
- You must have at least one tumor that can be measured or seen on a scan.
- You are over 18 years old and expected to live at least 3 more months.
- Your major organs (like heart, liver, kidneys) and bone marrow must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a combination of three drugs—sintilimab, chidamide, and azacitidine—for people newly diagnosed with a rare type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that is in early stages (I or II). The goal is to see if this combination is safe and effective.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Hear when a new Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.